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Diabetes mellitus is the most prevalent metabolic disorder contributing to significant 
morbidity and mortality in humans. Many preventative and therapeutic agents have been 
developed for normalizing glycemic profile in patients with diabetes. In addition to various 
pharmacologic strategies, many non-pharmacological agents have also been suggested to 
improve glycemic control in patients with diabetes. Trehalose is a naturally occurring 
disaccharide which is not synthesized in human but is widely used in food industries. Some 
studies have provided evidence indicating that it can potentially modulate glucose metabolism 
and help to stabilize glucose homeostasis in patients with diabetes. Studies have shown that 
trehalose can significantly modulate insulin sensitivity via at least 7 molecular pathways 
leading to better control of hyperglycemia. In the current study, we concluded about possible 
anti-hyperglycemic effects of trehalose suggesting trehalose as a potentially potent non-
pharmacological agent for the management of diabetes.  
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Introduction  
The global prevalence of diabetes mellitus (DM) is rising exponentially [1]. This 
chronic disorder has paramount effects on various metabolic pathways as well as on the 
physiologic function of most organs and hence responsible for a wide variety of diabetes-
induced tissue dysfunctions known as diabetic complications [2, 3]. DM acts as a potent 
upstream event for many pathophysiologic mechanisms such as oxidative stress, inflammation, 
apoptosis and fibrosis which in turn induce the onset and progression of various forms of 
diabetic complications [4, 5]. Diabetes and its related complications impose a significant 
economic burden to the health systems and are responsible for many cases of disabilities and 
death in human [6, 7]. Therefore, normalizing glycemic profile and management of chronic 
hyperglycemia by pharmacological and non-pharmacological approaches are of paramount 
importance [8-10]. 
Trehalose is a disaccharide carbohydrate which is synthesized in many organisms 
ranging from bacteria to plants [11]. Although this natural sweetener molecule could not be 
synthesized in humans, it has some biological roles and effects on various metabolic pathways 
after consumption [12-14]. It is used extensively in the food industry, biotechnology and 
pharmaceutical industry. There is some evidence suggesting that it can potentially modulate 
glucose homeostasis [15, 16]. In the current review, we assessed the possible links between 
trehalose usage and DM in humans and whether it can modulate hyperglycemia toward the 
physiologic state.  
Trehalose, Biochemistry and Biology  
Trehalose is a naturally-occurring, non-reducing sugar formed by two D-glucose 
molecules linked by α-1,1-glycosidic bindings [17, 18]. This unreactive disaccharide is 
synthesized by a wide variety of species ranging from prokaryotes, fungi, invertebrates, insects, 
plants, and yeast and has significant metabolic roles including storage of energy [18]. The 
synthetic form of Trehalose was produced by enzymatic processes for the first time in 1995 
[19], and at present is extensively used in food industries as a stabilizer for protecting foods 
against dryness, freezing and osmotic pressure stresses [16]. In comparison with sucrose, 
trehalose has lower sweetener potency and is broken into two glucose molecules by the enzyme 
trehalase and provides a high amount of energy [18, 20].  
It also acts as an osmo-protectant especially against ethanol and osmotic pressures. It 
provides a stabilizing effect for the cellular membrane by increasing the plasma membrane 
tolerance to dehydration, shriveling and temperature shock [21]. It has suggested that non-
reactivity and high stability properties of trehalose are due to the very low energy of the 
glycoside oxygen bindings to its two hexose rings [21]. Although trehalase enzyme is widely 
expressed in human and founded in the brush border of mucosal intestinal cells, no evidence 
exists about the trehalose production in human [18].  
Molecular Mechanisms Involved in Insulin Resistance  
Insulin resistance; which is a key event in the development of dysmetabolic states such 
as non-alcoholic fatty liver disease, DM and metabolic syndrome; is a complicated condition 
involving several molecular mechanisms [22, 23]. In a previous review we found that at least 
10 molecular pathways are included in peripheral resistance to insulin including reduced 
response to circulatory insulin such as up-regulation of PTP1B (protein-tyrosine phosphatase 
1B), inflammatory mediators and adipokines secretion, oxidative stress, ER (endoplasmic 
reticulum) stress, lower IRS‐1 (insulin receptor substrates‐1) phosphorylation, adipocytes 
metabolism, augmented insulin degradation, defect in GLUT‐4 (glucose transporter-4) activity, 
lower capacity of receptors to binding to insulin and mitochondrial dysfunction [23]. As a 
result, any pharmacologic or non-pharmacological agents which modulate these molecular 
mechanisms may be also able to regulate insulin sensitivity [8, 23-25].         
Possible Links between Trehalose and Diabetes Mellitus    
Some recent evidence have shown that trehalose can potentially modulate glucose 
homeostasis [15, 16]. In following sections, we examine these potentials of trehalose (table 1).  
1. Trehalose and Insulin Sensitivity  
Trehalose can potentially increase insulin sensitivity and improve insulin resistance in 
diabetic milieu [26]. This effect is exerted either directly on glucose signaling pathways or 
indirectly via alleviating pathophysiologic pathways such as oxidative stress, inflammation 
and/or improvement in lipid metabolism [26]. Arai et al in 2010 demonstrated that trehalose 
induces insulin sensitivity by several mechanisms including a reduction in inflammatory 
mediators such as MCP-1 (monocyte chemotactic protein-1), TNF-α (tumor necrosis factor-
alpha), and PAI-1 (plasminogen activator inhibitor–1) and improvement in adipocytes function 
by inhibition of lipid accumulation [26]. Arai and coworkers in 2013 presented further evidence 
indicating that 8 weeks trehalose consumption mitigates insulin resistance by adiponectin 
secretion, lipid profile correction and up-regulation of the IRS-1 and IRS-2 mRNA expression 
in obese mice [27]. Mizote and colleagues in 2016 found in a clinical trial that trehalose 
improved insulin resistance by adiponectin release and PAI-1 down-regulation in people at risk 
of metabolic syndrome [15]. Higgins et al in 2018 showed that trehalose is a potent analog for 
ALOXE3 (Epidermis-type Lipoxygenase 3) which in turn induces insulin sensitivity via 
PPAR-γ (peroxisome proliferator-activated receptor gamma) dependent mechanism in mice 
[28]. These evidence strongly suggest that trehalose induces insulin sensitivity in 
hyperlipidemia or in the hyperglycemic milieu.   
2. Trehalose and Postprandial Glucose/Insulin Secretion  
Reducing insulin secretion is the most known effects of trehalose on glucose 
homeostasis and is supported by various studies [26, 29, 30]. Arai and coworkers in 2010 
observed that trehalose markedly reduced the fasting insulin levels in comparison with glucose 
and maltose in rats [26]. Oku et al in 2000 reported that trehalose intake has remarkable effects 
on blood glucose in people with higher levels of trehalase activity than people with low 
trehalase activity. Trehalose had a potent inhibitory effect on insulin release in these subjects 
[29]. Also, Maki et al in 2009 reported that trehalose intake in obese men elicited lower 
postprandial insulin secretory response than to that of glucose [30]. Yoshizane and colleagues 
in 2017 observed in healthy volunteers that trehalose ingestion did not induce a rapid rise in 
postprandial glucose and did not stimulate GIP (gastric inhibitory protein) secretion [16]. These 
evidence clearly confirm that trehalose has weaker stimulatory effects on postprandial insulin 
release in comparison with other sugars [26, 30]. It has also been suggested that the trehalase 
acts in a manner dependent on insulin level demonstrating the intricate relationship between 
insulin levels and trehalase activity [31]. These finding also showed that trehalose reduces 
insulin dependent postprandial adipocyte accumulation which is regularly seen after 
carbohydrate consumption [16, 26].    
3. Trehalose and Glucose Metabolism  
Trehalose has shown to normalize glucose metabolic pathways [32, 33]. Sato et al in 
1999 demonstrated that animals consuming parenteral trehalose have improved glucose 
metabolism and nutritional indices than after consuming other disaccharides [32]. Also, van 
Can and coworkers in 2012 provided data indicating trehalose improves glucose metabolism 
in patients with glucose intolerance [34]. Yasugi et al in 2017 suggested that animals using 
trehalose as nutrient have improved metabolism which is gained via adaptation [35]. These 
evidence implied that trehalose may directly modulate glucose metabolism but the exact 
mechanisms need to be elucidated in further studies. 
4. Trehalose and Lipid Metabolism 
Correction of the lipid profile may be one of the other possible mechanisms by which 
trehalose improves glucose homeostasis [26]. There is growing evidence that trehalose directly 
modulates secretion of adipokines and increases adiponectin release leading to improvement 
in lipid metabolism [15, 27]. Since sub-optimal lipid profile is closely linked to insulin 
resistance disorders as well as DM; we suggest that any improvement in lipid metabolism could 
also effectively improve insulin sensitivity [15].    
 
Figure 1; Molecular mechanisms by which trehalose prevents and reverses the 
effects of DM on glucose homeostasis 
 
5. Trehalose and Improvement in Islet Function   
Trehalose consumption could improve pancreatic islet function in several ways [36, 
37]. Emerging evidence indicates that trehalose prevents apoptosis and autophagy processes, 
both of which are involved in beta cell dysfunction [36-38]. Beattie and coworkers in 1997 
provided first direct evidence suggesting long-term trehalose consumption improves pancreatic 
beta cells' efficiency in patients with diabetes [37]. Pan et al in 2018 demonstrated that trehalose 
is able to suppress apoptosis in diabetic animals [38]. Lin et al in 2016 established an 
experimental study confirming trehalose diminishes pathogenic mechanisms such as apoptosis, 
pyroptosis and autophagy probably by its anti-oxidant and anti-inflammatory potentials in 
pancreatic cells of diabetic rats [39]. This beneficial effect was previously suggested by Xu and 
coworkers in 2013 in neuronal cells where they showed that trehalose improved diabetes-
induced neuronal defects by correcting the autophagy process [40]. Chen and colleagues in 
2016 reported that lower concentration of trehalose markedly improves islet function by 
ameliorating islet amyloid polypeptide synthesis in patients with diabetes [36]. These data 
strongly suggest that trehalose consumption may improve islet function and glucose 
homeostasis. 
        
6. Trehalose and Oxidative Stress  
Free radical overload and oxidative stress occur in patients with diabetes [41]. 
Metabolic derangements which develop during DM markedly induces free radical generation 
which in turn results in an increase in peripheral resistance to insulin [32, 41]. Some 
experiments suggest that trehalose can potentially reduce oxidative stress [42].  Mizunoe and 
colleagues in 2018 showed that trehalose protects against oxidative damages by Nrf2 (nuclear 
factor erythroid 2–related factor 2; a nuclear factor regulates antioxidant elements expression)-
dependent antioxidant elements up-regulation in cell lines of mouse hepatocytes [42]. Alvarez-
Peral et al in 2002 demonstrated that trehalose has a protective role against oxidative stress in 
Candida albicans [43]. Moreover, Tang et al in 2017 reported that trehalose diminished 
mitochondria-induced oxidative stress by regulation of the autophagy process in patients with 
osteoarthritis [44]. Echigo et al in 2012 found that trehalose improved oxidative damages in 
the brain after subarachnoid bleeding in experimental studies, both in vitro and in vivo [45]. 
These data in addition to other evidence demonstrates potent antioxidative effects of trehalose 
which contributes to the potential antihyperglycaemic effects of this non-reducing disaccharide 
[46].  
   
Molecular Pathway Influence of Trehalose  References 
Insulin Sensitivity 
Improves insulin sensitivity by several mechanisms 
including IRS up-regulation, PPAR-γ dependent 
mechanism and ameliorating other pathophysiologic 
pathways 
[26-28] 
Insulin Secretion  Reduces postprandial insulin release  [26, 29, 30] 
Glucose Metabolism  
Improves glucose metabolism and regulates 
postprandial glucose levels  [32-35] 
Lipid Metabolism  
Corrects lipid metabolism by modulating 
postprandial insulin release  [15, 26, 27] 
Islet Function  Improves beta cell function  [36-40] 
Oxidative Stress 
Attenuates oxidative stress leading to improved 
insulin sensitivity  [42-46] 
Inflammatory 
Cytokines 
Prevent/suppresses inflammatory responses  [26, 45, 47, 
48] 
Table 1; Various influences of trehalose on DM, trehalose consumption can 
modulate glucose homeostasis via at least 7 molecular mechanisms 
(IRSs=insulin receptor substrates, PPAR-γ= Peroxisome proliferator-
activated receptor gamma)  
 
7. Trehalose and Inflammatory Cytokines 
Inflammatory mediators have significant roles in the pathophysiology of many 
complications of DM [49, 50]. It has been well established that the expression/release of 
inflammatory mediators is up-regulated in patients with insulin resistance [4, 51]. There is 
growing evidence that trehalose inhibits inflammatory responses by ameliorating inflammatory 
mediators  [26, 47]. Consumption of trehalose markedly reduced inflammatory cytokines such 
as TNF-α, MCP-1 and PAI-1 in experimental studies [26, 48]. In addition, Echigo et al in 2012 
showed that trehalose ameliorated the inflammation in in-vitro and in-vivo models of 
subarachnoid hemorrhage [45]. This suggests that intake of trehalose improves insulin 
sensitivity at least partly via attenuating inflammatory responses [48].  
8. Other Possible Links  
There is some evidence suggesting other potential relationships between trehalose 
consumption and insulin sensitivity such as thermogenesis [52], stabilizing insulin [53], and 
improvement in mitochondrial dysfunction [44]. But these molecular pathways need further 
investigation by in vivo and in vitro studies.    
Trehalose has been shown to inhibit multiple glucose transporter (GLUT) receptors through 
binding in the inward open conformation of these receptors [54, 55]. By inhibiting GLUT 
function trehalose could potentially prevent excess glucose absorption in the intestine.  It has 
also reported that trehalose reduces postprandial glycemic excursions in patients with impaired 
glucose tolerance [56]. This suggests that ingestion of trehalose with daily meals could 
potentially prevent hyperglycemia and development of diabetes.  
 
    
Conclusion  
Trehalose is a non-reducing carbohydrate widely produced by different species but not 
in the human. It has lower sweetener potency than sucrose and is broken down into two 
molecules of glucose by trehalase enzyme activity. This enzyme is expressed in humans and is 
localized in the brush border of endothelial cells of the intestine. In addition to providing energy 
in other species, trehalose can modulate glucose homeostasis by at least 7 molecular pathways. 
Data suggests that trehalose consumption improve hyperglycemic milieu by ameliorating 
pathophysilogical mechanisms such as oxidative stress, inflammation and apoptosis, 
improving beta cell function, reducing postprandial insulin release and normalizing lipid 
profile. These molecular mechanisms suggest the role of trehalose as a potential non-
pharmacological agent for the management of glycaemia in patients with diabetes, however, 
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